• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Cancer-related nucleoside-triphosphatase (NTPCR)

ACP10443

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP10443 Target Namentpcr
Target SynonymsNTPCR; C1orf57; Cancer-related nucleoside-triphosphatase; NTPase; EC 3.6.1.15; Nucleoside triphosphate phosphohydrolaseFormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Expression Range2-190
Protein LengthFull Length of Mature ProteinPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ9BSD7
Background Information
  • Uniprot Id

    Q9BSD7

  • Target Species

    Human

  • Target Name

    NTPCR

  • Target Full Name

    Cancer-related nucleoside-triphosphatase

  • Target Function

    Has nucleotide phosphatase activity towards ATP, GTP, CTP, TTP and UTP. Hydrolyzes nucleoside diphosphates with lower efficiency.

  • Target Protein Families

    THEP1 NTPase family

  • Target Synonyms

    NTPCR; C1orf57; Cancer-related nucleoside-triphosphatase; NTPase; EC 3.6.1.15; Nucleoside triphosphate phosphohydrolase

  • Target Background

    The protein encoded by this gene is a non-specific nucleoside triphosphatase that is slow-acting in vitro. This gene is overexpressed in many tumor tissues, and while it is not essential for the cell, overexpression is cytotoxic. However, the cytotoxicity is not related to its triphosphatase activity.

Inquire Recombinant Human Cancer-related nucleoside-triphosphatase (NTPCR) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification